AbbVie Inc.
ABBVNYSELatest results at a glance
Insights from the latest company results and reports · filed 31 Jul 2026
Second-Quarter Earnings Exceed Expectations
Reported adjusted diluted EPS of $3.65 for the quarter ended June 30, 2026, exceeded the same-quarter consensus estimate of $3.61.
Guidance Adjusted for Acquisition
The company updated its 2026 adjusted diluted EPS guidance range to $13.87-$14.07, incorporating a $0.14 dilutive impact from the proposed Apogee Therapeutics acquisition.
Rinvoq Receives EU Approval
The European Commission approved Rinvoq for non-segmental vitiligo, marking the first systemic medication approval in the EU for this condition.
Apogee Acquisition Announced
AbbVie announced a definitive agreement to acquire Apogee Therapeutics, including pipeline candidates for inflammatory and immunological diseases, with an anticipated close in the third quarter of 2026.
Company research evidence
Checked financial measurements with the values, reporting periods and measurement basis shown together. This evidence is available independently of the AI report.
Loading evidence…
Deep Dive Research
Source-linked company research for ABBV
Revenue segmentation
Loading segment disclosures…